A multicenter, single-arm, phase II study to evaluate a safety and efficacy of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed/refractory Waldenström Macroglobulinemia.
Phase of Trial: Phase II
Latest Information Update: 15 Nov 2018
At a glance
- Drugs Obinutuzumab (Primary)
- Indications Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- 28 Sep 2018 Status changed from not yet recruiting to recruiting.
- 27 Apr 2018 New trial record